Managing lung cancer during coronavirus disease 2019 pandemic

dc.contributor.authorKhalifeh, Ibrahim M.
dc.contributor.authorTfayli, Arafat Hussein
dc.contributor.departmentInternal Medicine
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:43:12Z
dc.date.available2025-01-24T11:43:12Z
dc.date.issued2021
dc.description.abstractCoronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared as a pandemic by the World Health Organization. As this disease continues to spread worldwide, it has posed enormous challenges on the healthcare of several diseases, especially cancer, because hospital facilities have invested health resources for patients with COVID-19. In-deed, patients with lung cancer are particularly vulnerable because of their poor baseline lung function and cancer-related treatment. In ad-dition, once infected, they are at an increased risk of pulmonary complications from COVID-19. Oncologists are thus facing a challenge as how to balance the treatment plans to control the disease while protecting the patients with lung cancer from COVID-19. In fact, it is crucial to provide individualized treatment recommendations to limit the risks during these difficult times. This review highlights the key challenges that oncologists face when diagnosing COVID-19 among patients with lung cancer and examines the current recommendations from available literature, clinical expertise, and expert opinions regarding managing lung cancer in the era of COVID-19. It also explores the treatment approach recommended for patients with lung cancer while avoiding putting them at excessive risk of contracting COVID-19 infection. © 2020 by Turkish Thoracic Society.
dc.identifier.doihttps://doi.org/10.5152/TurkThoracJ.2021.20110
dc.identifier.eid2-s2.0-85103549162
dc.identifier.urihttp://hdl.handle.net/10938/30232
dc.language.isoen
dc.publisherAVES
dc.relation.ispartofTurkish Thoracic Journal
dc.sourceScopus
dc.subjectCoronavirus disease 2019
dc.subjectLung cancer
dc.subjectPrevention and control
dc.subjectTherapy
dc.subjectGranulocyte colony stimulating factor
dc.subjectAnxiety
dc.subjectCancer adjuvant therapy
dc.subjectCancer chemotherapy
dc.subjectCancer screening
dc.subjectCancer surgery
dc.subjectCancer therapy
dc.subjectChemoradiotherapy
dc.subjectComputer assisted tomography
dc.subjectCoughing
dc.subjectDepression
dc.subjectDyspnea
dc.subjectFatigue
dc.subjectFebrile neutropenia
dc.subjectFever
dc.subjectFollow up
dc.subjectHuman
dc.subjectLung function
dc.subjectLung injury
dc.subjectLung metastasis
dc.subjectMyalgia
dc.subjectNon small cell lung cancer
dc.subjectNuclear magnetic resonance imaging
dc.subjectPalliative therapy
dc.subjectPandemic
dc.subjectPostoperative care
dc.subjectReal time polymerase chain reaction
dc.subjectRespiratory distress
dc.subjectReview
dc.subjectRisk factor
dc.subjectSeptic shock
dc.subjectSmall cell lung cancer
dc.subjectSmoking
dc.subjectTelemedicine
dc.titleManaging lung cancer during coronavirus disease 2019 pandemic
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2021-2826.pdf
Size:
133.53 KB
Format:
Adobe Portable Document Format